Gilead Sciences (GILD -2.85%) didn't have a bad first quarter, but investors didn't find it inspiring either. After publishing its earnings report after market close Thursday, the company saw its share price decline in excess of 2% the following day. That contrasted unfavorably with the 0.6% rise of the S&P 500 index that trading session.Flat sales, but a dramatic flip on the bottom lineFor the period, Gilead's revenue clocked in at $6.67 billion, essentially flat over the same quarter of 2024. The company ...

Gilead Sciences, Inc. (GILD) reported lower-than-expected first-quarter 2025 results. Adjusted earnings per share (EPS) of $1.81 missed the Zacks Consensus Estimate by a penny. In the year-ago quarter, the company reported a loss per share of $1.32. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)Total revenues of $6.7 billion also missed the Zacks Consensus Estimate of $6.8 billion. Revenues were roughly flat year over year as lower Veklury (remdesivir) and oncology sales were offs ...

Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Company Participants Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial Officer Dietmar Berger - Chief Medical Officer Andrew Dickinson - CFO Cindy Perettie - EVP, Kite Conference Call Participants Michael Yee - Jefferies Carter Gould - Cantor Fitzgerald James Shin - Deutsche Bank Salveen Richter - Goldman Sachs Tyler Van Buren - TD Cowen Daina Graybosch - Leerink Par ...

Gilead Sciences (GILD) came out with quarterly earnings of $1.81 per share, missing the Zacks Consensus Estimate of $1.82 per share. This compares to loss of $1.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -0.55%. A quarter ago, it was expected that this HIV and hepatitis C drugmaker would post earnings of $1.67 per share when it actually produced earnings of $1.90, delivering a surprise of 13.77%.Over the last four quar ...

Q125 Financial Results 10 December 2024 April 24, 2025 Forward-Looking Statements Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead's ability to achieve its f ...

GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.3 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.1 billion Foster City, CA, April 24, 2025 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2025 results of operations. "Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management," said Daniel O'Day, Gilead's Chairman and Chi ...

文章核心观点 - Zacks Premium为投资者提供多种利用股市和自信投资的方式，其风格评分与Zacks Rank配合可帮助投资者挑选股票，吉列德科学公司值得投资者关注 [1][10][14] Zacks Premium服务内容 - 提供Zacks Rank和Zacks Industry Rank每日更新、Zacks 1 Rank List全访问权、股票研究报告和高级股票筛选器 [1] - 包含Zacks Style Scores [2] Zacks Style Scores介绍 - 与Zacks Rank一同开发，基于三种投资方法对股票评级，帮助投资者挑选未来30天跑赢市场的股票 [3] - 按价值、增长、动量特征将股票评级为A、B、C、D或F，分数越好表现越佳 [4] - 分为价值评分、增长评分、动量评分和VGM评分四类 [4] 各类评分说明 - 价值评分利用多种比率识别有吸引力和被低估的股票 [4] - 增长评分考虑预期和历史盈利、销售和现金流，发掘长期可持续增长的股票 [5] - 动量评分利用价格和盈利预期变化等因素，确定买入高动量股票的有利时机 [6] - VGM评分综合三种风格评分，帮助找到价值、增长和动量俱佳的公司，是与Zacks Rank配合的最佳指标之一 [7] Style Scores与Zacks Rank配合方式 - Zacks Rank利用盈利预期修正帮助投资者创建成功投资组合，自1988年以来1（强力买入）股票年均回报率达25.41% [8][9] - 为实现回报最大化，应购买Zacks Rank为1或2且Style Scores为A或B的股票，3（持有）股票也需有A或B的分数 [10] - 选择股票时盈利预期修正方向是关键因素，4（卖出）或5（强力卖出）评级股票即便Style Scores为A和B也有下跌风险 [11] 吉列德科学公司情况 - 总部位于加州福斯特城，是开发艾滋病药物的先驱，产品组合广泛，HIV业务表现强劲，2024年HIV业务销售额达196亿美元，同比增长8% [12] - Zacks Rank为3（持有），VGM评分为B，价值风格评分为B，因前瞻市盈率13.31受价值投资者关注 [13] - 2025财年有五位分析师上调盈利预期，Zacks共识预期增至每股7.86美元，平均盈利惊喜为19.5% [13]

Wall Street analysts expect Gilead Sciences (GILD) to post quarterly earnings of $1.73 per share in its upcoming report, which indicates a year-over-year increase of 231.1%. Revenues are expected to be $6.83 billion, up 2.2% from the year-ago quarter.The consensus EPS estimate for the quarter has undergone an upward revision of 0.9% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Ahead ...

文章核心观点 - 吉利德科学公司将于4月24日盘后公布2025年第一季度财报 市场对其销售和盈利有预期 公司过往盈利表现良好 但Q1业绩受多种因素影响 近期有产品审批进展 股价表现优于行业 投资方面建议观望或持有 [1][2][13] 分组1：财报预期 - 2025年第一季度销售和盈利的Zacks共识估计分别为68.3亿美元和每股1.73美元 [1] - 2025年盈利估计在过去60天从每股7.80美元增至7.86美元 2026年从8.12美元增至8.30美元 [1] 分组2：盈利惊喜历史 - 公司在过去四个季度均超盈利预期 平均惊喜率为19.47% 上一季度超预期13.77% [2] 分组3：模型预测 - 公司盈利ESP为+3.07% 目前Zacks排名为3 盈利超预期几率增加 [4] 分组4：影响Q1业绩因素 - 公司HIV业务因新医保模式和低收入补贴计划折扣影响 第一季度可能放缓 [7] - 肝病组合因对病毒性肝炎药物需求增加和新药销售 第一季度销售可能提升 [8][9] - 细胞疗法产品销售因竞争逆风 在待报告季度可能下降 [10] - 乳腺癌药物Trodelvy第一季度需求可能强劲 [11] - 第一季度研发和销售、一般及行政费用可能下降 [11] 分组5：近期关键进展 - 公司lenacapavir在美国和欧盟的批准申请正在审核中 FDA给予优先审核 目标行动日期为2025年6月19日 [12] - 欧盟委员会给予seladelpar治疗PBC有条件上市许可 [12] 分组6：股价表现和估值 - 公司股价年初至今上涨14.4% 跑赢行业、板块和标普500指数 [13] - 公司股票目前市盈率为13.13倍 高于均值但低于大盘制药行业 [16] 分组7：投资论点 - 公司拥有领先的HIV治疗组合 开发创新疗法受投资者认可 若lenacapavir获批将巩固HIV业务 [18] - 公司肿瘤组合多元化业务 Trodelvy需求强劲 但细胞疗法业务受竞争压力 [19] - 公司战略交易和收购令人鼓舞 [19] 分组8：投资建议 - 建议投资者目前观望 持有股票的投资者可继续持有 公司股息收益率有吸引力 [21]

文章核心观点 文章围绕吉利德科学公司展开，介绍其股价表现、盈利预测、估值情况等，还提及行业排名，认为公司有投资价值 [1][2][7] 股价表现 - 最新收盘价112.39美元，较前一日上涨0.45%，跑赢标普500、道指和纳斯达克指数 [1] - 过去一个月股价下跌3.08%，跑赢医疗板块和标普500指数 [1] 盈利预测 即将发布的财报 - 4月24日发布财报，预计每股收益1.73美元，较去年同期增长231.06% [2] - 预计营收68亿美元，较去年同期增长1.67% [2] 年度预测 - 预计每股收益7.87美元，较去年增长70.35% [3] - 预计营收285.6亿美元，较去年下降0.67% [3] 分析师评级 - 分析师对公司盈利预测上调，反映对公司业务和盈利能力的积极态度 [4] - 公司目前Zacks排名为2（买入），过去一个月Zacks共识每股收益预测上调0.16% [6] 估值情况 - 公司远期市盈率14.22，低于行业平均的17.83 [7] - 公司PEG比率0.73，行业平均为1.43 [7] 行业排名 - 医疗-生物医学和遗传学行业Zacks行业排名75，位居所有250多个行业前31% [8] - 研究显示排名前50%的行业表现是后50%的两倍 [8]